Expanding Treatment Options for Breast Cancer Patients and Women at High Risk
Bayer, a global leader in women’s healthcare, is taking a significant step forward in addressing the needs of breast cancer patients and women at high risk for breast cancer. The company has announced the initiation of OASIS 4, a Phase III study that aims to investigate the efficacy and safety of elinzanetant as a non-hormonal treatment for vasomotor symptoms caused by endocrine therapy.
The Impact of Vasomotor Symptoms
Vasomotor symptoms, also known as hot flashes, are a common adverse reaction of endocrine therapy in breast cancer patients. These symptoms can have a significant impact on the quality of life and treatment continuation for these patients. Currently, there are no effective non-hormonal treatment options available to address these symptoms.
“For women treated with endocrine therapy for breast cancer, vasomotor symptoms can intensively affect their quality of life and treatment continuation, which in turn might impact the effectiveness of their cancer therapy and hence their survival,” said Dr. Christian Rommel, member of the Executive Committee of Bayer AG’s Pharmaceutical Division and Global Head of Research and Development.
The OASIS 4 Phase III Study
The OASIS 4 study plans to randomize approximately 400 patients at about 95 centers in 15 countries. It will investigate the efficacy and safety of elinzanetant 120 mg once daily in women at high risk for breast cancer and breast cancer patients with vasomotor symptoms caused by endocrine therapy.
About Vasomotor Symptoms
Vasomotor symptoms, such as hot flashes, are a result of the withdrawal of estradiol and the hyperactivation of the thermoregulatory pathway in the brain. These symptoms can have a negative impact on sleep, mood, and quality of life.
About Menopause
Menopause is an inevitable process that occurs in women in their late 40s or early 50s. The decline in hormone production by the ovaries can lead to various symptoms, including hot flashes, sleep disturbances, and mood changes. Managing menopause is crucial for maintaining a woman’s health, quality of life, and productivity.
About Elinzanetant
Elinzanetant is an innovative non-hormonal development compound that addresses vasomotor symptoms during menopause. It modulates estrogen-sensitive neurons in the brain to alleviate hot flashes. The Phase III clinical development program with elinzanetant, called OASIS, comprises four Phase III studies.
Bayer’s Commitment to Women’s Healthcare
Bayer is committed to delivering science for a better life in women’s healthcare. The company offers a wide range of effective birth control methods, therapies for menopause management, and treatments for gynecological diseases. Bayer is also focused on finding new treatment options for menopause and gynecological diseases through its research and development efforts.
Additionally, Bayer aims to provide 100 million women in low- and middle-income countries with access to family planning by 2030. This commitment aligns with the company’s comprehensive sustainability measures and the Sustainable Development Goals of the United Nations.
About Bayer
Bayer is a global enterprise dedicated to the life sciences fields of healthcare and nutrition. The company aims to generate a positive impact by supporting efforts to address the challenges presented by a growing and aging global population. Bayer’s brand stands for trust, reliability, and quality.
Photo: Freepik.com
